Patent ID: 7022701

Claim:
A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor wherein said disorder is a psychiatric disorder or a neurodegenerative disorder in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I wherein Q is SO 2 , CO, CONR 9 or CSNR 10 ; n is an integer of 2 or 3; R 1 and R 2 are each independently H, halogen, CN, OCO 2 R 12 , CO 2 R 13 , CONR 14 R 15 , CNR 16 NR 17 R 18 , SO m R 19 , NR 20 R 21 , OR 22 , COR 23 or a C 1 –C 6 alkyl, C 2 –C 6 alkenyl, C 2 –C 6 alkynyl, C 3 –C 6 cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R 3 and R 4 are each independently H or an optionally substituted C 1 –C 6 alkyl group; R 5 and R 6 are each independently H or a C 1 –C 6 alkyl, C 2 –C 6 alkenyl, C 2 –C 6 alkynyl, C 3 –C 6 cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted, or R 5 and R 6 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing an additional heteroatom selected from O, N or S; R 7 is H, halogen, or a C 1 –C 6 alkyl, C 1 –C 6 alkoxy, aryl or heteroaryl group each optionally substituted; R 8 is an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S; m is 0 or an integer of 1 or 2; R 9 and R 10 are each independently H or a C 1 –C 6 alkyl, aryl or heteroaryl group each optionally substituted; R 12 , R 13 , R 19 and R 23 are each independently H or a C 1 –C 6 alkyl, C 2 –C 6 alkenyl, C 2 –C 6 alkynyl, C 3 –C 6 cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R 14 , R 15 and R 22 are each independently H or an optionally substituted C 1 –C 6 alkyl group; and R 16 , R 17 , R 18 , R 20 and R 21 are each independently H or an optionally substituted C 1 –C 4 alkyl group; or R 20 and R 21 may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; or the stereoisomers thereof or the pharmaceutically acceptable salts thereof.